Renovaro INC 10-Q quarterly reports

Lunai Bioworks reports Q3 2026 financial results, highlighting a net loss of $2.57 million and ongoing efforts to secure capital for its AI-driven precision medicine platform.

Lunai Bioworks Inc. reported a net income of $2.82 million for the quarter ended September 30, 2025, a significant improvement from a prior-year loss, driven by one-time gains and reduced operating expenses, despite ongoing legal challenges and a 'going concern' warning.

Renovaro Inc.'s Q3 2025 results reveal a net income of $189,176, a significant improvement from the prior year, but the company acknowledges substantial doubt about its ability to continue as a going concern.

Renovaro Inc.'s Q2 2025 financial results reveal a substantial increase in net loss primarily due to a significant goodwill impairment charge.

Renovaro Inc. is restating its Q1 2025 financial statements due to a material misstatement related to the exercising of certain warrants, and reports a significant goodwill impairment charge.

Renovaro Inc. restated its Q3 2024 financial statements due to material misstatements related to warrant exercises and an impairment charge, impacting previously reported assets, losses, and earnings per share.

Renovaro Inc.'s Q1 2025 results show a significant net loss due to a substantial goodwill impairment, despite a decrease in operating expenses and a gain from contingent consideration.

Renovaro Inc. has restated its financial statements for the quarter ended March 31, 2024, due to a material misstatement related to the valuation of indefinite-life intangible assets.

Renovaro Inc. reported its Q3 2024 results, which included the acquisition of Renovaro Cube and a significant increase in operating expenses, leading to a net loss.

Renovaro Inc. reports a net loss for the second quarter of 2024, while highlighting progress in its oncology and HIV therapeutic programs.